Search

Author

Subject

Date issued

Has File(s)

Search Results

Results 331-340 of 384 (Search time: 0.006 seconds).
  • Authors: Xinyue, Xiang; Lihua, Huang; Yong, Fang;  Advisor: -;  Co-Author: - (2023)

    Reduced physical activity (PA) was the strongest predictor of all-cause mortality in patients with chronic obstructive pulmonary disease (COPD). This scoping review aimed to map the evidence on the current landscape of physical activity, barriers and facilitators, and assessment tools across COPD patients.

  • Authors: Jianli, Ma; Chuantao, Zhang; Kaijie, Dang;  Advisor: -;  Co-Author: - (2023)

    Spherical pneumonia is an extremely rare condition that is difficult to diagnose. It is a specific type of lung infection that often manifests as a round or round-like mass on chest imaging. Spherical pneumonia is easily misdiagnosed as a pulmonary tumor; therefore, awareness of this disease must be strengthened.

  • Authors: Na, Zhang; Yang, Li; Zeguo, Feng;  Advisor: -;  Co-Author: - (2023)

    The simultaneous use of drugs with different mechanisms of analgesic action is a strategy for achieving effective pain control while minimizing dose-related side effects. Choline was described to potentiate the analgesic action of parecoxib sodium at small doses in several inflammatory pain models. However, these findings are still very limited, and more associated data are required to confirm the effectiveness of the combined choline and parecoxib sodium therapy against inflammatory pain.

  • Authors: Andrea, Wolf; Jan A., Stratmann; Shabnam, Shaid;  Advisor: -;  Co-Author: - (2023)

    Immune checkpoint inhibitors (ICIs) have improved outcomes for patients with advanced non-small cell lung cancer (NSCLC) versus chemotherapy in clinical trials. In Germany, ICIs have been used clinically since 2015 for patients with advanced/metastatic NSCLC without epidermal growth factor receptor (EGFR)/anaplastic lymphoma kinase (ALK) aberrations. As part of I-O Optimise, a multinational research program utilizing real-world data on thoracic malignancies, we describe real-world treatment patterns and survival following reimbursement of ICIs for advanced NSCLC in Germany.